CA2656327A1 - A method of modifying a macromolecule without prior extraction from a sample - Google Patents
A method of modifying a macromolecule without prior extraction from a sample Download PDFInfo
- Publication number
- CA2656327A1 CA2656327A1 CA002656327A CA2656327A CA2656327A1 CA 2656327 A1 CA2656327 A1 CA 2656327A1 CA 002656327 A CA002656327 A CA 002656327A CA 2656327 A CA2656327 A CA 2656327A CA 2656327 A1 CA2656327 A1 CA 2656327A1
- Authority
- CA
- Canada
- Prior art keywords
- dna
- sample
- macromolecule
- bisulfite
- modification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 101
- 229920002521 macromolecule Polymers 0.000 title claims abstract description 26
- 238000000605 extraction Methods 0.000 title claims abstract description 14
- 239000000126 substance Substances 0.000 claims abstract description 10
- 239000000543 intermediate Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 45
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 39
- 230000004048 modification Effects 0.000 claims description 37
- 238000012986 modification Methods 0.000 claims description 37
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 36
- 210000001519 tissue Anatomy 0.000 claims description 32
- 210000002700 urine Anatomy 0.000 claims description 29
- 239000003153 chemical reaction reagent Substances 0.000 claims description 26
- 238000000746 purification Methods 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 21
- 238000005869 desulfonation reaction Methods 0.000 claims description 21
- 230000006326 desulfonation Effects 0.000 claims description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 13
- 238000011534 incubation Methods 0.000 claims description 13
- 239000006166 lysate Substances 0.000 claims description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
- 150000002632 lipids Chemical class 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 235000014633 carbohydrates Nutrition 0.000 claims description 9
- 230000011987 methylation Effects 0.000 claims description 9
- 238000007069 methylation reaction Methods 0.000 claims description 9
- 238000001574 biopsy Methods 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 150000001720 carbohydrates Chemical class 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 210000001124 body fluid Anatomy 0.000 claims description 7
- 239000010839 body fluid Substances 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 6
- 238000005576 amination reaction Methods 0.000 claims description 6
- 239000012188 paraffin wax Substances 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 239000002207 metabolite Substances 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000005909 Kieselgur Substances 0.000 claims description 4
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical group [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 238000006481 deamination reaction Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 238000004513 sizing Methods 0.000 claims description 4
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 4
- 230000006287 biotinylation Effects 0.000 claims description 3
- 238000007413 biotinylation Methods 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 230000002438 mitochondrial effect Effects 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 102000035195 Peptidases Human genes 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 210000000170 cell membrane Anatomy 0.000 claims description 2
- 239000000356 contaminant Substances 0.000 claims description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 2
- 230000009615 deamination Effects 0.000 claims description 2
- 230000022811 deglycosylation Effects 0.000 claims description 2
- 230000030609 dephosphorylation Effects 0.000 claims description 2
- 238000006209 dephosphorylation reaction Methods 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 claims description 2
- 210000003038 endothelium Anatomy 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 210000000981 epithelium Anatomy 0.000 claims description 2
- 238000003682 fluorination reaction Methods 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 230000013595 glycosylation Effects 0.000 claims description 2
- 238000006206 glycosylation reaction Methods 0.000 claims description 2
- 210000004020 intracellular membrane Anatomy 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 108091070501 miRNA Proteins 0.000 claims description 2
- 239000000693 micelle Substances 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 210000002706 plastid Anatomy 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 235000019833 protease Nutrition 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 2
- 238000000527 sonication Methods 0.000 claims description 2
- 229940035893 uracil Drugs 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 125000003473 lipid group Chemical group 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 79
- 239000000523 sample Substances 0.000 description 61
- 239000008188 pellet Substances 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 23
- 102100030943 Glutathione S-transferase P Human genes 0.000 description 19
- 101001010139 Homo sapiens Glutathione S-transferase P Proteins 0.000 description 19
- 239000011534 wash buffer Substances 0.000 description 18
- 239000003550 marker Substances 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 230000008836 DNA modification Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 230000007067 DNA methylation Effects 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 239000002699 waste material Substances 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 9
- 238000007855 methylation-specific PCR Methods 0.000 description 9
- 239000013024 dilution buffer Substances 0.000 description 8
- 210000002307 prostate Anatomy 0.000 description 8
- 238000007399 DNA isolation Methods 0.000 description 7
- 239000011536 extraction buffer Substances 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 108010067770 Endopeptidase K Proteins 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000008096 xylene Substances 0.000 description 6
- 238000007400 DNA extraction Methods 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000012148 binding buffer Substances 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000009987 spinning Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical class CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 238000007427 paired t-test Methods 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- -1 R-Actin Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 210000005267 prostate cell Anatomy 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 101100491335 Caenorhabditis elegans mat-2 gene Proteins 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 101000993380 Homo sapiens Hypermethylated in cancer 1 protein Proteins 0.000 description 1
- 102100031612 Hypermethylated in cancer 1 protein Human genes 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- YGJHZCLPZAZIHH-UHFFFAOYSA-N N-Nitrosodi-n-butylamine Chemical compound CCCCN(N=O)CCCC YGJHZCLPZAZIHH-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 208000012191 childhood neoplasm Diseases 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000002349 difference gel electrophoresis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000006607 hypermethylation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000002976 reverse transcriptase assay Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Sampling And Sample Adjustment (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention encompasses a method of modifying a macromolecule without prior extraction from a sample by converting the macromolecule in the sample with a chemical, removing or converting chemical intermediates, if necessary; and purifying the resulting modified macromolecule.
Description
A METHOD OF MODIFYING A MACROMOLECULE WITHOUT PRIOR
EXTRACTION FROM A SAMPLE
BACKGROUND OF THE INVENTION
The present invention encompasses a method of modifying a macromolecule without prior extraction from a sample by converting the macromolecule in the sample with a chemical, removing or converting chemical intermediates, if necessary; and purifying the resulting modified macromolecule.
One method used by vertebrates and higher plants to regulation gene expression is the methylation of cytosines found in CpG islands located in promoter regions of various genes. In order to study this method of gene regulation, techniques were developed to discriminate methylated cytosines from unmethylated cytosines. One method is to chemically treat DNA in such a way that the cytosines are converted to uracils while 5-methyl-cytosines are not significantly converted. Frommer et al. (1992). A systematic investigation ori the critical parameters of the modification procedure has also been made.
Grunau et al. (2001). The treated DNA may be used as template for methylation specific PCR (MSP). DNA methylation and methods related thereto are discussed for instance in US patent publication nurnbers 20020197639,20030022215,20030032026,20030082600,20030087258, 20030096289,20030129620,20030148290,20030157510,20030170684, 20030215842,20030224040,20030232351,20040023279,20040038245, 20040048275,20040072197,20040086944,20040101843,20040115663, 20040132048,20040137474,20040146866,20040146868,20040152080, 20040171118,20040203048,20040241704,20040248090,20040248120, 20040265814,20050009059,20050019762,20050026183,20050053937, 20050064428,20050069879,20050079527,20050089870,20050130172, 20050153296, 20050196792, 20050208491, 20050208538, 20050214812, 20050233340, 20050239101, 20050260630, 20050266458, 20050287553 and US patent numbers 5786146, 6214556, 6251594, 6331393 and 6335165.
DNA modification kits are commercially available, they convert purified genomic DNA with unmethylated cytosines into genomic lacking unmethylated cytosines but with additional uracils. The treatment is a two-step chemical process consisting a deamination reaction facilitated. by bisulfite and a desulfonation step facilitated by sodium hydroxide: Typically the deamination reaction is performed as a liquid and is terminated by incubation on ice followed by adding column binding buffer. Following solid phase binding and washing the DNA is eluted and the desulfonation reaction is performed in a liquid.
Adding ethanol terminates the reaction and the modified DNA is cleaned up.by precipitation. However, both commercially available kits (Zymo and Chemicon) perform the desulfonation reaction while the DNA is bound on the column and washing the column terminates the reaction. The treated DNA is eluted from the column ready for MSP assay. The modification is tedious and has many steps that cause yield loss and increase operator er"ror. All of the available modification procedures begin with purified genomic DNA, which is a tedious process that also has many steps that cause yield loss and increase operator error.
SUMMARY OF THE INVENTION
The present invention encompasses a method of modifying a.
macromolecule without prior extraction from a sample by converting the macromolecule in the sample with a chemical, removing or converting chemical intermediates, if necessary; and purifying the resulting modified macromolecule.
BRIEF DESCRIPTION OF THE DRAWING
Figure 1: Shows that DNA modification in without isolation from a biological sample is equivalent to such modification after isolation.
DETAILED DESCRIPTION
The present invention encompasses a method of modifying a macromolecule without prior extraction from a sample by converting the macromolecule in the sample with a chemical, removing or converting chemical intermediates, if necessary; and purifying the resulting modified macromolecule.
The macromolecules can be any known in the art including, without 30. limitation, DNA, RNA, cellular metabolites, lipids, carbohydrates and proteins.
The DNA can be any known in the art including, without limitation, viral, nucleic, mitochondrial, plastid, bacterial and synthetic. The RNA can be any known in the art including, without limitation, rtRNA, tRNA, miRNA, rRNA and mRNA.
EXTRACTION FROM A SAMPLE
BACKGROUND OF THE INVENTION
The present invention encompasses a method of modifying a macromolecule without prior extraction from a sample by converting the macromolecule in the sample with a chemical, removing or converting chemical intermediates, if necessary; and purifying the resulting modified macromolecule.
One method used by vertebrates and higher plants to regulation gene expression is the methylation of cytosines found in CpG islands located in promoter regions of various genes. In order to study this method of gene regulation, techniques were developed to discriminate methylated cytosines from unmethylated cytosines. One method is to chemically treat DNA in such a way that the cytosines are converted to uracils while 5-methyl-cytosines are not significantly converted. Frommer et al. (1992). A systematic investigation ori the critical parameters of the modification procedure has also been made.
Grunau et al. (2001). The treated DNA may be used as template for methylation specific PCR (MSP). DNA methylation and methods related thereto are discussed for instance in US patent publication nurnbers 20020197639,20030022215,20030032026,20030082600,20030087258, 20030096289,20030129620,20030148290,20030157510,20030170684, 20030215842,20030224040,20030232351,20040023279,20040038245, 20040048275,20040072197,20040086944,20040101843,20040115663, 20040132048,20040137474,20040146866,20040146868,20040152080, 20040171118,20040203048,20040241704,20040248090,20040248120, 20040265814,20050009059,20050019762,20050026183,20050053937, 20050064428,20050069879,20050079527,20050089870,20050130172, 20050153296, 20050196792, 20050208491, 20050208538, 20050214812, 20050233340, 20050239101, 20050260630, 20050266458, 20050287553 and US patent numbers 5786146, 6214556, 6251594, 6331393 and 6335165.
DNA modification kits are commercially available, they convert purified genomic DNA with unmethylated cytosines into genomic lacking unmethylated cytosines but with additional uracils. The treatment is a two-step chemical process consisting a deamination reaction facilitated. by bisulfite and a desulfonation step facilitated by sodium hydroxide: Typically the deamination reaction is performed as a liquid and is terminated by incubation on ice followed by adding column binding buffer. Following solid phase binding and washing the DNA is eluted and the desulfonation reaction is performed in a liquid.
Adding ethanol terminates the reaction and the modified DNA is cleaned up.by precipitation. However, both commercially available kits (Zymo and Chemicon) perform the desulfonation reaction while the DNA is bound on the column and washing the column terminates the reaction. The treated DNA is eluted from the column ready for MSP assay. The modification is tedious and has many steps that cause yield loss and increase operator er"ror. All of the available modification procedures begin with purified genomic DNA, which is a tedious process that also has many steps that cause yield loss and increase operator error.
SUMMARY OF THE INVENTION
The present invention encompasses a method of modifying a.
macromolecule without prior extraction from a sample by converting the macromolecule in the sample with a chemical, removing or converting chemical intermediates, if necessary; and purifying the resulting modified macromolecule.
BRIEF DESCRIPTION OF THE DRAWING
Figure 1: Shows that DNA modification in without isolation from a biological sample is equivalent to such modification after isolation.
DETAILED DESCRIPTION
The present invention encompasses a method of modifying a macromolecule without prior extraction from a sample by converting the macromolecule in the sample with a chemical, removing or converting chemical intermediates, if necessary; and purifying the resulting modified macromolecule.
The macromolecules can be any known in the art including, without 30. limitation, DNA, RNA, cellular metabolites, lipids, carbohydrates and proteins.
The DNA can be any known in the art including, without limitation, viral, nucleic, mitochondrial, plastid, bacterial and synthetic. The RNA can be any known in the art including, without limitation, rtRNA, tRNA, miRNA, rRNA and mRNA.
The cellular metabolite can be any known in the art including, without limitation, those produced by a metaboiic cycle or enzymatic effects. The lipid can be any known in the art including, without limitation, liposomes, cell membrane lipids, intracellular membrane lipids and extracellular lipids. 'The carbohydrate can be any known in the art including, without limitation, protein-bound carbohydrates and nucleic acid-bound carbohydrates. 'The protein can be any known in the art including, without limitation, intracelluiar and extracellular.
The modification is can be any known in the art including bisutfite and biotinyfation of DNA or RNA, fluorination and methylation of RNA, heating, liposome formation, micelle formation, uni-layer formation and bilayer formation of lipids, oxidation, de-oxidation; amination and de-amination of carbohydrates and phosphorylation, dephosphorylation, methylation, biotinylation, amination, deamination, glycosylation and deglycosylation of proteins. 20070148670;
Chuang et al. (2007); Emmerechts et al. (2007); Frommer et al. (1992); Grunau et al. (2001); Hurd et al. (2007); Jin et al. (2007); Oakeley (1999); Rathi et al.
(2003); Rein et al. (1998); Sambrook et al. (2000); Wu et al. (2007).
The sample can be any known in the art including, without limitation, tissue, body fluid, a biopsy sample, and preserved tissue. The tissue can be any known in the art including, without limitation, whole organs, dissected organs, epithelium, neural, gastrointestinal, muscle, cardiac, mucosal and endothelium. The body fluid can be any known in the art including, without limitation, whole blood, plasma, urine, saliva, vitreous and serum. The.biopsy sample can be any known in the art including, without limitation, fine needle aspirate, tissue section and skin sample. The preserved tissue can be any known in the art including, without limitation, fresh frozen, paraffin embedded and preserved in a preservation reagent. The preservation reagent can be any known in the art including, without limitation, formalin, RNAfater and dimethylsulfoxide.
The purification can be any known in the art including, without limitation, particle-based, precipitation, centrifugation, electrophoretic and charge switch.
The particle-based purification can be any known in the art including, without limitation, affinity, sizing and magnetic. The sizing particle can be any known in the art including, without limitation, silica-based and diatomaceous earth.
The electrophoretic separation purification can be any known in the art including, without limitation, by size and/or charge. The electrophoretic separation purification can be any known in the art including, without limitation, by a gel formed of low molecular weight polymers and/or capillary.
The present invention provides a rapid and efficient method for obtaining bisulfite modified DNA. The method described herein effectively eliminates numerous steps of the previous methods thus reducing possible error while producing superior results. In addition considerable time savings of four to five hours are also realized.
The present invention provides a method of extracting and modifying DNA by obtaining a DNA sample; incubating the sample with an amount of a bisulfite and for a time and under conditions sufficient to convert at least ninety-five percent of the non-methylated cytosine residues in the DNA to uracil resides; binding the DNA in the sample to a column; washing the bound DNA to remove contaminants; incubating the column-bound DNA with a desulfonation reagent for a time and under conditions sufficient for desulfonation to occur;
washing the bound DNA to remove the desulfonation reagent; and eluting the bisulfite modified DNA from the column.
The DNA can be at a concentration of from about 0.01 to about 30 pg and can be obtained by any method known in the art and can be purified DNA
or DNA obtained directly from a cell lysate. For instance, the cell lysate can be formed from any suitable tissue by any method known in the art and directly treated with a bisulfite reagent. Cell lysis can be by for instance, proteinase and/or high salt concentration and/or detergent, sonication, freeze-thaw treatment or mechanical disruption. Any cell sample is suitable for use herein and can be obtained from tissue, body fluid, biopsy sample or preserved tissue.
The bisulfite reagent can be any known in the art, including, without limitation, sodium bisulfite or meta bisulfite. Other reagents are discussed for instance in US patent publications 20050089898, 20050095623 and 20050153308.
The incubation conditions of step b are about 1-16 hours at 50-95 C with or without Thermocycling. Thermocycling can be for instance 3 hours at 70 C, 1 hour at 90 C or cycling between 50 C and 95 C.
The column can be any known in the art, preferably, it is silica-based or diatomaceous earth. The desulfonation can be by any method known in the art and is preferably performed with sodium hydroxide and an alcohol. Preferably, the alcohol is isopropanol or ethanol. More preferably, when the colurnn is 5 silica-based, the alcohol is ethanol and when the column is diatomaceous earth, the alcohol is isopropanol. The desulfonation preferably occurs from about 0-30, preferably about 5-15 and more preferably about 15 minutes at about 0 C to about 50 C. Preferably, the temperature is about room temperature.
The modified macromolecule can be eluted by any method known in the art, including, without limitation with water or a suitable buffer.
The following examples are provided to illustrate but not limit the claimed invention. All references cited herein are hereby incorporated herein by reference.
Example I
Rapid bisulfite modification of DNA from a cell lysate obtained from fresh frozen paraffin embedded tissue Microfuge tube containing cell culture pellet in PBS
= Add 100 - l DNA extraction buffer (75mM NaCl, 25mM EDTA, and 0.5%
Tween 20), incubate 56 C for 10minutes.
= Proceed with 3M NaOH addition described below Or a microfuge tube containing (up to) 5 10 micron FFPE block slices.
The FFPE slices require deparaffination:
= Add 1 ml of Xylene to the tube and mix by inverting several times : Incubate at RT for 5 min and centrifuge at full speed for 5minutes at RT
= Remove the supernatant without removing any pellet = Repeat the I mt Xylene extraction = Add 1 ml EtOH (100%) to the pellet and gently mix by inverting = Centrifuge full speed for 5 minutes at RT
= Carefully remove the EtOH by pipetting without removing any of the pellet = Repeat the EtOH wash = Dry the pellet in a 37 C heat block with the microfuge tubes open Extraction/modification procedure for FFPE samples = Add 90 N1 extraction buffer (10mM Tris, pH 8.0, 150mM NaCI, 2mM
EDTA, and 0.5% SDS) and 10 pl proteinase K and incubate overnight at = After incubation the extract should be clear, if not add 10 p proteinase K
and incubate for 1 hr = Repeat until lysis is clear and proceed with 3M NaOH addition described below.
= Add 1/10 volume 3M NaOH and incubate 56 C for 10minutes.
= Add 2 volumes of a saturated solution of sodium bisulfite pH 5.0 with 10mM hydroquinone, incubate at 70 C for 3 hours in the dark.
= Stop the reaction'by incubating on ice for 10 minutes. Add 0_5 volumes of Isopropanol and gently vortex or pipette up and down.
== Add the sample to a Qiagen DNA purification column (QiaAmp DNA
purification kit), spin I min and empty waste tube;
= Add 500 NI AW1 wash buffer, spin 1 min and empty waste tube;
= Add 500 Ul AW2 wash buffer, spin 1 min and empty waste tube;
= Add 200 pl desulfonation buffer (300 mM NaOH, 80% Isopropanol), incubate 10 min room temperature, spin 1 min and empty waste tube;
= Add 500 NI AW2 wash buffer, spin 1 min, empty waste tube and spin 1 min, = Add 500 lal AW2 wash buffer, spin 1 min, empty waste tube and spin 1 min, = Elute with 50 NI TE, spin 1 min into new 1.5 ml microfuge tube and store at -20 C
The efficiency of the procedure is assayed using quantitative PCR and (3-Actin using GSTPI as markers. The (3-Actin promoter is not methylated and the marker is designed to serve as a control for the modification procedure.
The Ct value produced by this marker is reflective of the number of genome equivalents added to the assay. Whereas the GSTP1 promoter is methylated epigenetically and may be reflective of a cancerous state. Therefore the GHSTP1 marker Ct value is more variable and usually greater than the ¾-Actin Ct value. The Prostate FFPE blocks were obtained from Asterand. The "Zymo" treatment refers commercially available DNA modification kit sold as EZ
DNA Methylation Kit from Zymo Research. A 2 Step procedure refers to two separate procedures that use a DNA purification kit (Qiagen QiaAmp mini DBNA purification kit) and a DNA modification kit such as the Zymo kit. The Zymo 1 step procedure is identical to the ID procedure until the 3M NaOH step where the Zymo DNA modification procedure is followed replacing the 3M
NaOH with M-Dilution buffer.
The results shown in Table 1 using cell culture pellets indicate that the 1 Step method produces lower Ct values and thus superior results when compared to the Qiagen/Zymo 2 Step procedure. Slatistically, a paired T test indicates the methods, using the R-Actin marker, are significantly different from each other with a P value of 0.00006 while the GSTP1 marker had a P value of 0.0001. The results shown in Table 2 indicate that ID 1 step produces lower Ct values when compared to the Zymo 1 Step method with the P-Actin marker produces a P value of 0.02 and the GSTPI marker results in a P value of 0.003 However, the results shown in Table 1 using prostate FFPE blocks indicate the opposite results from the cell cultures with the Zymo 2 Step producing lower Ct values then the 1 step method. The (i-Actin marker results indicate that the methods are significantly different with a P value of 0.021 while the GSTP1 results suggest that they maybe different with a P value of 0.054.
The different results suggested that the extraction buffer for cell culture might not be sufficient to lysis tissue blocks. Table 4 results compares the ID 1 Step and the Zymo 1 Step methods using a more aggressive extraction buffer switching the Tween to SDS while using prostate tissue blocks. The ID 1 Step method once again shows superior results suggesting that the failure to produce superior results in Table 3 was due to the extraction buffer. The R-Actin marker results indicates that the methods are significantly different with a P value of 0.0008 while the GSTP1 results suggest that they maybe different with a P value of 0.056. Since the QPCR assay method only has 40 cycles, once an assay fails to produce Ct's then it is not significant to compare with assays that produce Ct's. If the two samples that had assays that failed then the P values would be 0.0025, which indicates the methods using the GSTP1 marker are significantly different.
Table 1: Results comparing the 1 Step procedure to the Qiagen/Zymo (Zymo) 2 Step procedure Cell Culture LnCAP 1 x 10 Cell eltets, 2 pellets tested in du Iicate Treatment Procedure Marker Ct SD P value ID 1 Step P-Actin . 26.94 0.24 0.00006 Z mo 2 Step P-Actin 27.80 0.29 ID 1 Step GSTPI 27.66 0.20 0.0001 Z mo 2 Step GSTP1 28.54 0.23 Table 2: Results comparing the 1 Step procedure to the Zymo 1 Step procedure -Cell Culture LnCAP 1 x 10 Cell eliets, 2 pellets tested in du licate Treatment Procedure Marker Ct SD P value ID 1 Ste P-Actin 27.60 0.18 0.020 Zymo 1 Step P-Actin 29.90 0.08 ID I Ste p GSTP1 28.48 0.07 0.00.3 Zymo 1 Step GSTP1 30.87 0.18 Table 3: Results comparing the 1 Step procedure to the Qiagen/Zymo (Zymo) 2 Ste procedure Prostate FFPE Blocks Using The Cell Culture Extraction Buffer Treatment Tissue Procedure Average SD Average = SD
Block -Actin Ct GSTP1 Ct ID 1 1 Step 30.68 0.08 32.64 0.27 ID 2 1 Step 33.84 0.22 37.20 = 0.33 ID 3 1 Step 31.26 0.04 35.19 0.16 ID 4 1 Step 34.21 0.03 38.57 0.08 Zymo 1 2 Step 29.68 0.19 33.40 0.07 Zymo 2 2 Step 28.72 0:04 32.87 0.19 Z mo 3 2 Step 27.69 0.01 32.11 0.22 Zymo 4 2 Step 27.62 0.04 33.65 0.25 P value 0.021 00.054 -Table 4: Results comparing the 1 Step procedure to the Zymo 1 Step procedure using Prostate FFPE blocks.
Prostate FFPE Blocks Usin The FFPE Extraction Buffer Treatment Tissue Block P-Actin P-Actin GSTPI GSTP1 Ct SD Ct SD
Z rno 12 35.16 0.10 40 0.00 ID 12 31.21 0.04 40 0.00 Zymo 16 34.41 0.12 35.76 0.79 ID = 16 30.23 0.33 31.98 0.25 Zymo 18 35.69 0.13 40.00 0.00 ID 18 32.63 0.16 39.27 1.03 Zymo 20 33.08 = 0.17 36.07 0.05 ID 20 28.29 0.03 32.34 0.19 Control Plasmid 23.15 0.79 22.86 0.34 P value 00.0008 00.056 Example 2 Bisulfite treatment of DNA obtained from urine The purpose of this experiment was to compare the DEM kit versus the Zymo EZ Modification kit on purified DNA obtained from LnCAP cells and urine.
Ten normalized random samples were divided between the two kits - 5 Samples per Kit (DEM and Zymo) = PCR performed in duplicate using Fast Start Taq (GSTP1, R-Actin, and APC) ANOVA analysis indicates a P value of 0.663 and a Paired T-Test indicates that there is no statistical difference between DEM and Zymo for GSTP1.
ANOVA analysis indicates a P value of 0.008 and a Paired T-Test indicates that there is a statistical difference between DEM and Zymo for B-Actin.
= The results indicate that Zymo and the DEM kit are equivalent for GSTPI
= The DEM kit was optimized for tissue as opposed to purified DNA further optimization within ProMU could lead to lower CT values.
= The DEM kit demonstrates a higher p-Actin value R Actin GSTP1 One Way ANOVA P= 0.000 One Way ANOVA P= 0.663 DEM (Mean CT) 34.990 DEM (Mean CT) 31.30 DEM STDEV 1.341 DEM STDEV 0.839 Zymo (Mean CT) 33.270 Zymo (Mean CT) 31.140 Zymo STDEV 1.240 Zymo STDEV 0.773 Number Kit (3-Actin GSTP1 APC
1 DEM 33.8 30.4 34.0 .2 DEM 34.8 30.5 33.2 3 DEM 37.8 31.8 34.1 4 DEM 35.1 32.2 33.9 5 DEM 35.7 32.5 34.4 6 DEM 35.6 32.2 34.3 7 DEM 33.4 30.5 32.4 8 DEM 33.4 30.4 32.3 9 DEM 35.8 31.5 33.3 10 DEM 34.5 31.0 32.4 1 Zymo 32.7 32.4 33.4 2 Zymo 32.3 30.8 31.5 3 Zymo 35.6 31.9 33.3 4 Zymo 34.5 31.8 33.2 5 Zymo 34.2 31.6 32.6 6 Zymo 34.2 31.4 32.5 7 Zymo 32.1 30.4 31.5 8 Zymo 32.2 30.5 31.5 9 Zymo 32.3 30.2 31.6.
10 Zymo 32.6 30.4 31.6 The binding of crude lysate containing DNA or purified genomic DNA is uniquely bound to the silica-gel based column utilizing the high concentration of salt that is present from the bisulfite conversion.
Ethanol is added to the sample prior to binding only to dissolve the 5 conversion reagent.
= Add 1/10 volume M-Dilution Buffer and incubate 70 C for 20 minutes to chemically denature the double stranded DNA
= Add 2 volurnes of CT conversion reagent (Zymo), incubate at 70 C for 3 hours in the dark.
10 = Add 0.5 volumes of ethanol (100%) and gently vortex or pipette up and down.
Microfuge tube containing purified DNA from urine at a starting volume of 45 NI
= Proceed with M-Dilution Buffer addition described below = Or a microfuge tube containing (up to) 5 10 micron FFPE block slices of a formalin fixed paraffin embedded cell culture pellet which is known to express GSTP1 hyper Methylation.
The FFPE slices require deparaffination:
. = Add 1 ml of Xylene to the tube and mix by inverting, several times = Incubate at RT for 5 min and centrifuge at 13,200rpm for 5 min at RT
= Remove the supernatant without removing any pellet = Repeat the 1 ml Xylene extraction -= Add 1 ml EtOH (100%) to the pellet and gently mix by inverting = Centrifuge at 13,200 rpm for 5 min at RT
= Carefully remove the EtOH by pipetting without removing any of the pellet -= Repeat the EtOH wash = Dry the pellet and remove the residual ethanol in a 37 C heat block with the microfuge tubes open for approximately 10 minutes Extraction/modification procedure for FFPE samples = Add 35 NI buffer ATL (Qiagen) and 10 NI of proteinase K (Qiagen) and incubate overnight at 56 C
= After incubation the extract should be clear and homogeneous = Proceed with M-Dilution Buffer (Zymo Research) addition described below = Add the sample to a Qiagen DNA purification column (QiaAmp Micro DNA purification kit), spin 1 min at 13,200 rpm and empty waste tube;
= Add 500 NI AW1 wash buffer, spin 1 min at 13,200 rpm and empty waste tube;
= Add 200 pl desulfonation buffer (300 mM NaOH, 90% Ethanol), incubate 20 min room temperature, spin 1 min at 13,200 rpm and empty waste tube;
= Add 500 NI AW2 wash buffer, spin 1 min (13,200 rpm), empty waste tube and spin 3 min (13,200 rpm).
= Elute with 20-25 pi buffer AE, TE, or Nuclease Free Water. Incubate column for three min at room temperature and spin 9 min into new 1.5 ml microfuge tube and store at -20 C or -30 C foe =
The modification is can be any known in the art including bisutfite and biotinyfation of DNA or RNA, fluorination and methylation of RNA, heating, liposome formation, micelle formation, uni-layer formation and bilayer formation of lipids, oxidation, de-oxidation; amination and de-amination of carbohydrates and phosphorylation, dephosphorylation, methylation, biotinylation, amination, deamination, glycosylation and deglycosylation of proteins. 20070148670;
Chuang et al. (2007); Emmerechts et al. (2007); Frommer et al. (1992); Grunau et al. (2001); Hurd et al. (2007); Jin et al. (2007); Oakeley (1999); Rathi et al.
(2003); Rein et al. (1998); Sambrook et al. (2000); Wu et al. (2007).
The sample can be any known in the art including, without limitation, tissue, body fluid, a biopsy sample, and preserved tissue. The tissue can be any known in the art including, without limitation, whole organs, dissected organs, epithelium, neural, gastrointestinal, muscle, cardiac, mucosal and endothelium. The body fluid can be any known in the art including, without limitation, whole blood, plasma, urine, saliva, vitreous and serum. The.biopsy sample can be any known in the art including, without limitation, fine needle aspirate, tissue section and skin sample. The preserved tissue can be any known in the art including, without limitation, fresh frozen, paraffin embedded and preserved in a preservation reagent. The preservation reagent can be any known in the art including, without limitation, formalin, RNAfater and dimethylsulfoxide.
The purification can be any known in the art including, without limitation, particle-based, precipitation, centrifugation, electrophoretic and charge switch.
The particle-based purification can be any known in the art including, without limitation, affinity, sizing and magnetic. The sizing particle can be any known in the art including, without limitation, silica-based and diatomaceous earth.
The electrophoretic separation purification can be any known in the art including, without limitation, by size and/or charge. The electrophoretic separation purification can be any known in the art including, without limitation, by a gel formed of low molecular weight polymers and/or capillary.
The present invention provides a rapid and efficient method for obtaining bisulfite modified DNA. The method described herein effectively eliminates numerous steps of the previous methods thus reducing possible error while producing superior results. In addition considerable time savings of four to five hours are also realized.
The present invention provides a method of extracting and modifying DNA by obtaining a DNA sample; incubating the sample with an amount of a bisulfite and for a time and under conditions sufficient to convert at least ninety-five percent of the non-methylated cytosine residues in the DNA to uracil resides; binding the DNA in the sample to a column; washing the bound DNA to remove contaminants; incubating the column-bound DNA with a desulfonation reagent for a time and under conditions sufficient for desulfonation to occur;
washing the bound DNA to remove the desulfonation reagent; and eluting the bisulfite modified DNA from the column.
The DNA can be at a concentration of from about 0.01 to about 30 pg and can be obtained by any method known in the art and can be purified DNA
or DNA obtained directly from a cell lysate. For instance, the cell lysate can be formed from any suitable tissue by any method known in the art and directly treated with a bisulfite reagent. Cell lysis can be by for instance, proteinase and/or high salt concentration and/or detergent, sonication, freeze-thaw treatment or mechanical disruption. Any cell sample is suitable for use herein and can be obtained from tissue, body fluid, biopsy sample or preserved tissue.
The bisulfite reagent can be any known in the art, including, without limitation, sodium bisulfite or meta bisulfite. Other reagents are discussed for instance in US patent publications 20050089898, 20050095623 and 20050153308.
The incubation conditions of step b are about 1-16 hours at 50-95 C with or without Thermocycling. Thermocycling can be for instance 3 hours at 70 C, 1 hour at 90 C or cycling between 50 C and 95 C.
The column can be any known in the art, preferably, it is silica-based or diatomaceous earth. The desulfonation can be by any method known in the art and is preferably performed with sodium hydroxide and an alcohol. Preferably, the alcohol is isopropanol or ethanol. More preferably, when the colurnn is 5 silica-based, the alcohol is ethanol and when the column is diatomaceous earth, the alcohol is isopropanol. The desulfonation preferably occurs from about 0-30, preferably about 5-15 and more preferably about 15 minutes at about 0 C to about 50 C. Preferably, the temperature is about room temperature.
The modified macromolecule can be eluted by any method known in the art, including, without limitation with water or a suitable buffer.
The following examples are provided to illustrate but not limit the claimed invention. All references cited herein are hereby incorporated herein by reference.
Example I
Rapid bisulfite modification of DNA from a cell lysate obtained from fresh frozen paraffin embedded tissue Microfuge tube containing cell culture pellet in PBS
= Add 100 - l DNA extraction buffer (75mM NaCl, 25mM EDTA, and 0.5%
Tween 20), incubate 56 C for 10minutes.
= Proceed with 3M NaOH addition described below Or a microfuge tube containing (up to) 5 10 micron FFPE block slices.
The FFPE slices require deparaffination:
= Add 1 ml of Xylene to the tube and mix by inverting several times : Incubate at RT for 5 min and centrifuge at full speed for 5minutes at RT
= Remove the supernatant without removing any pellet = Repeat the I mt Xylene extraction = Add 1 ml EtOH (100%) to the pellet and gently mix by inverting = Centrifuge full speed for 5 minutes at RT
= Carefully remove the EtOH by pipetting without removing any of the pellet = Repeat the EtOH wash = Dry the pellet in a 37 C heat block with the microfuge tubes open Extraction/modification procedure for FFPE samples = Add 90 N1 extraction buffer (10mM Tris, pH 8.0, 150mM NaCI, 2mM
EDTA, and 0.5% SDS) and 10 pl proteinase K and incubate overnight at = After incubation the extract should be clear, if not add 10 p proteinase K
and incubate for 1 hr = Repeat until lysis is clear and proceed with 3M NaOH addition described below.
= Add 1/10 volume 3M NaOH and incubate 56 C for 10minutes.
= Add 2 volumes of a saturated solution of sodium bisulfite pH 5.0 with 10mM hydroquinone, incubate at 70 C for 3 hours in the dark.
= Stop the reaction'by incubating on ice for 10 minutes. Add 0_5 volumes of Isopropanol and gently vortex or pipette up and down.
== Add the sample to a Qiagen DNA purification column (QiaAmp DNA
purification kit), spin I min and empty waste tube;
= Add 500 NI AW1 wash buffer, spin 1 min and empty waste tube;
= Add 500 Ul AW2 wash buffer, spin 1 min and empty waste tube;
= Add 200 pl desulfonation buffer (300 mM NaOH, 80% Isopropanol), incubate 10 min room temperature, spin 1 min and empty waste tube;
= Add 500 NI AW2 wash buffer, spin 1 min, empty waste tube and spin 1 min, = Add 500 lal AW2 wash buffer, spin 1 min, empty waste tube and spin 1 min, = Elute with 50 NI TE, spin 1 min into new 1.5 ml microfuge tube and store at -20 C
The efficiency of the procedure is assayed using quantitative PCR and (3-Actin using GSTPI as markers. The (3-Actin promoter is not methylated and the marker is designed to serve as a control for the modification procedure.
The Ct value produced by this marker is reflective of the number of genome equivalents added to the assay. Whereas the GSTP1 promoter is methylated epigenetically and may be reflective of a cancerous state. Therefore the GHSTP1 marker Ct value is more variable and usually greater than the ¾-Actin Ct value. The Prostate FFPE blocks were obtained from Asterand. The "Zymo" treatment refers commercially available DNA modification kit sold as EZ
DNA Methylation Kit from Zymo Research. A 2 Step procedure refers to two separate procedures that use a DNA purification kit (Qiagen QiaAmp mini DBNA purification kit) and a DNA modification kit such as the Zymo kit. The Zymo 1 step procedure is identical to the ID procedure until the 3M NaOH step where the Zymo DNA modification procedure is followed replacing the 3M
NaOH with M-Dilution buffer.
The results shown in Table 1 using cell culture pellets indicate that the 1 Step method produces lower Ct values and thus superior results when compared to the Qiagen/Zymo 2 Step procedure. Slatistically, a paired T test indicates the methods, using the R-Actin marker, are significantly different from each other with a P value of 0.00006 while the GSTP1 marker had a P value of 0.0001. The results shown in Table 2 indicate that ID 1 step produces lower Ct values when compared to the Zymo 1 Step method with the P-Actin marker produces a P value of 0.02 and the GSTPI marker results in a P value of 0.003 However, the results shown in Table 1 using prostate FFPE blocks indicate the opposite results from the cell cultures with the Zymo 2 Step producing lower Ct values then the 1 step method. The (i-Actin marker results indicate that the methods are significantly different with a P value of 0.021 while the GSTP1 results suggest that they maybe different with a P value of 0.054.
The different results suggested that the extraction buffer for cell culture might not be sufficient to lysis tissue blocks. Table 4 results compares the ID 1 Step and the Zymo 1 Step methods using a more aggressive extraction buffer switching the Tween to SDS while using prostate tissue blocks. The ID 1 Step method once again shows superior results suggesting that the failure to produce superior results in Table 3 was due to the extraction buffer. The R-Actin marker results indicates that the methods are significantly different with a P value of 0.0008 while the GSTP1 results suggest that they maybe different with a P value of 0.056. Since the QPCR assay method only has 40 cycles, once an assay fails to produce Ct's then it is not significant to compare with assays that produce Ct's. If the two samples that had assays that failed then the P values would be 0.0025, which indicates the methods using the GSTP1 marker are significantly different.
Table 1: Results comparing the 1 Step procedure to the Qiagen/Zymo (Zymo) 2 Step procedure Cell Culture LnCAP 1 x 10 Cell eltets, 2 pellets tested in du Iicate Treatment Procedure Marker Ct SD P value ID 1 Step P-Actin . 26.94 0.24 0.00006 Z mo 2 Step P-Actin 27.80 0.29 ID 1 Step GSTPI 27.66 0.20 0.0001 Z mo 2 Step GSTP1 28.54 0.23 Table 2: Results comparing the 1 Step procedure to the Zymo 1 Step procedure -Cell Culture LnCAP 1 x 10 Cell eliets, 2 pellets tested in du licate Treatment Procedure Marker Ct SD P value ID 1 Ste P-Actin 27.60 0.18 0.020 Zymo 1 Step P-Actin 29.90 0.08 ID I Ste p GSTP1 28.48 0.07 0.00.3 Zymo 1 Step GSTP1 30.87 0.18 Table 3: Results comparing the 1 Step procedure to the Qiagen/Zymo (Zymo) 2 Ste procedure Prostate FFPE Blocks Using The Cell Culture Extraction Buffer Treatment Tissue Procedure Average SD Average = SD
Block -Actin Ct GSTP1 Ct ID 1 1 Step 30.68 0.08 32.64 0.27 ID 2 1 Step 33.84 0.22 37.20 = 0.33 ID 3 1 Step 31.26 0.04 35.19 0.16 ID 4 1 Step 34.21 0.03 38.57 0.08 Zymo 1 2 Step 29.68 0.19 33.40 0.07 Zymo 2 2 Step 28.72 0:04 32.87 0.19 Z mo 3 2 Step 27.69 0.01 32.11 0.22 Zymo 4 2 Step 27.62 0.04 33.65 0.25 P value 0.021 00.054 -Table 4: Results comparing the 1 Step procedure to the Zymo 1 Step procedure using Prostate FFPE blocks.
Prostate FFPE Blocks Usin The FFPE Extraction Buffer Treatment Tissue Block P-Actin P-Actin GSTPI GSTP1 Ct SD Ct SD
Z rno 12 35.16 0.10 40 0.00 ID 12 31.21 0.04 40 0.00 Zymo 16 34.41 0.12 35.76 0.79 ID = 16 30.23 0.33 31.98 0.25 Zymo 18 35.69 0.13 40.00 0.00 ID 18 32.63 0.16 39.27 1.03 Zymo 20 33.08 = 0.17 36.07 0.05 ID 20 28.29 0.03 32.34 0.19 Control Plasmid 23.15 0.79 22.86 0.34 P value 00.0008 00.056 Example 2 Bisulfite treatment of DNA obtained from urine The purpose of this experiment was to compare the DEM kit versus the Zymo EZ Modification kit on purified DNA obtained from LnCAP cells and urine.
Ten normalized random samples were divided between the two kits - 5 Samples per Kit (DEM and Zymo) = PCR performed in duplicate using Fast Start Taq (GSTP1, R-Actin, and APC) ANOVA analysis indicates a P value of 0.663 and a Paired T-Test indicates that there is no statistical difference between DEM and Zymo for GSTP1.
ANOVA analysis indicates a P value of 0.008 and a Paired T-Test indicates that there is a statistical difference between DEM and Zymo for B-Actin.
= The results indicate that Zymo and the DEM kit are equivalent for GSTPI
= The DEM kit was optimized for tissue as opposed to purified DNA further optimization within ProMU could lead to lower CT values.
= The DEM kit demonstrates a higher p-Actin value R Actin GSTP1 One Way ANOVA P= 0.000 One Way ANOVA P= 0.663 DEM (Mean CT) 34.990 DEM (Mean CT) 31.30 DEM STDEV 1.341 DEM STDEV 0.839 Zymo (Mean CT) 33.270 Zymo (Mean CT) 31.140 Zymo STDEV 1.240 Zymo STDEV 0.773 Number Kit (3-Actin GSTP1 APC
1 DEM 33.8 30.4 34.0 .2 DEM 34.8 30.5 33.2 3 DEM 37.8 31.8 34.1 4 DEM 35.1 32.2 33.9 5 DEM 35.7 32.5 34.4 6 DEM 35.6 32.2 34.3 7 DEM 33.4 30.5 32.4 8 DEM 33.4 30.4 32.3 9 DEM 35.8 31.5 33.3 10 DEM 34.5 31.0 32.4 1 Zymo 32.7 32.4 33.4 2 Zymo 32.3 30.8 31.5 3 Zymo 35.6 31.9 33.3 4 Zymo 34.5 31.8 33.2 5 Zymo 34.2 31.6 32.6 6 Zymo 34.2 31.4 32.5 7 Zymo 32.1 30.4 31.5 8 Zymo 32.2 30.5 31.5 9 Zymo 32.3 30.2 31.6.
10 Zymo 32.6 30.4 31.6 The binding of crude lysate containing DNA or purified genomic DNA is uniquely bound to the silica-gel based column utilizing the high concentration of salt that is present from the bisulfite conversion.
Ethanol is added to the sample prior to binding only to dissolve the 5 conversion reagent.
= Add 1/10 volume M-Dilution Buffer and incubate 70 C for 20 minutes to chemically denature the double stranded DNA
= Add 2 volurnes of CT conversion reagent (Zymo), incubate at 70 C for 3 hours in the dark.
10 = Add 0.5 volumes of ethanol (100%) and gently vortex or pipette up and down.
Microfuge tube containing purified DNA from urine at a starting volume of 45 NI
= Proceed with M-Dilution Buffer addition described below = Or a microfuge tube containing (up to) 5 10 micron FFPE block slices of a formalin fixed paraffin embedded cell culture pellet which is known to express GSTP1 hyper Methylation.
The FFPE slices require deparaffination:
. = Add 1 ml of Xylene to the tube and mix by inverting, several times = Incubate at RT for 5 min and centrifuge at 13,200rpm for 5 min at RT
= Remove the supernatant without removing any pellet = Repeat the 1 ml Xylene extraction -= Add 1 ml EtOH (100%) to the pellet and gently mix by inverting = Centrifuge at 13,200 rpm for 5 min at RT
= Carefully remove the EtOH by pipetting without removing any of the pellet -= Repeat the EtOH wash = Dry the pellet and remove the residual ethanol in a 37 C heat block with the microfuge tubes open for approximately 10 minutes Extraction/modification procedure for FFPE samples = Add 35 NI buffer ATL (Qiagen) and 10 NI of proteinase K (Qiagen) and incubate overnight at 56 C
= After incubation the extract should be clear and homogeneous = Proceed with M-Dilution Buffer (Zymo Research) addition described below = Add the sample to a Qiagen DNA purification column (QiaAmp Micro DNA purification kit), spin 1 min at 13,200 rpm and empty waste tube;
= Add 500 NI AW1 wash buffer, spin 1 min at 13,200 rpm and empty waste tube;
= Add 200 pl desulfonation buffer (300 mM NaOH, 90% Ethanol), incubate 20 min room temperature, spin 1 min at 13,200 rpm and empty waste tube;
= Add 500 NI AW2 wash buffer, spin 1 min (13,200 rpm), empty waste tube and spin 3 min (13,200 rpm).
= Elute with 20-25 pi buffer AE, TE, or Nuclease Free Water. Incubate column for three min at room temperature and spin 9 min into new 1.5 ml microfuge tube and store at -20 C or -30 C foe =
Example 3 Large Scale DNA Modification, Large scale DNA modification may be necessary to make paneis for quality control testing of methylation specific PCR methods and kits.
1. Denature 20 }ig of Prostate Cell Culture Cell line 22Rv1 genomic DNA (ATCC) in a total volume of 225 NI TE, plus 27.5 pl of a 3.0 M NaOH
solution. Incubate 10 minutes 37 C.
2. Add 2x volume Conversion reagent (Zymo); incubate 3 hr 70 C
followed by 10 min on ice.
Bind the DNA to a solid phase support by adding 2 ml of binding buffer containing the support matrix (Promega) and adding it to the syringe column vacuum apparatus. Using the vacuum, filter the matrix.
Using the vacuum, wash with the matrix with 1 ml 80% IPA
Add 2 ml OD desulfonation buffer (0.3 M NaOH in 80% IPA) and incubate at room temperature for 10 minutes. Using the vacuum, remove the buffer.
Using the vacuum, wash with I ml 80% IPA.
3. Remove the column from the syringe and place it in a 1.5 ml microfuge tube Elute 5 x 200 pl followed by addition of 1 ml EB
Table 5 depicts the results obtained.
Table 5 Marker Average Ct SD
Actin 33.1 0.2 APC 31.1 0.2 In this cell line the GSTPI promoter is known to be unmethylated therefore the lack of Ct values for this marker is expected.
Example 4 A modified protocol for fast and efficient bisulfite modification of genomic DNA
The EZ DNA Methylation Kit is provided by Zymo Research (Orange, CA) to perform bisulfite modification of DNA, As per manufacturer's recommendation the DNA sample to be modified is incubated with the bisulfite conversion reagent at 50 C for 12 - 16 hrs. These conditions have been modified to generate comparable quality bisulfite converted DNA in much less time. Several temperatures for different times we~e tested and demonstrated that incubation of DNA sample with bisulfite conversion reagent at 70 C for 1-3 hr provides efficient bisulfite modification comparable to modification conditions recommended in the kit. The data below show methylation specific PCR analysis with DNA samples incubated with bisulfite reagent at different temperatures for different times.
Figure 1 shows that Veridex modified protocol of conversion at 70 C, 2 or 3hr is equivalent to manufacturer recommended 50 C for 16 hrs. This innovation makes this procedure much faster.
Example 5 A quick and efficient protocol for DNA extraction and modification from paraffin Embedded Tissue Extraction of genomic DNA and its bisulfite modification prior to being used in a MSP reaction comprise very significant upstream procedures that are part of this in vitro diagnostic assay. These procedures can be time consuming involving many tedious steps and could also increase chances of sample contamination. By combining the use of a lysis buffer, 10 mM Tris pH 8.0, 150 mM NaCI, 2 mM EDTA, 0.5% SDS including proteinase K and a bisulfite modification kit, a quick and simple sample processing protocol to recover and modify minimal amounts of DNA available from these sample types has been developed.
The following steps were performed:
1. FFPE tissue (Biopsies) (5 x 10 p sections) are placed in Eppendorf tubes.
2. Spin the tube briefly and Add 500 pi Xylene, vortex briefly at medium speed.
3. Incubate at RT for 10 min. (During incubation at least at 2 intervals mix the sample by inverting several times).
4. Centrifuge at full speed for 10 min at room temperature.
5. Remove supernatant by carefully decanting the liquid without losing the pellet.
1. Denature 20 }ig of Prostate Cell Culture Cell line 22Rv1 genomic DNA (ATCC) in a total volume of 225 NI TE, plus 27.5 pl of a 3.0 M NaOH
solution. Incubate 10 minutes 37 C.
2. Add 2x volume Conversion reagent (Zymo); incubate 3 hr 70 C
followed by 10 min on ice.
Bind the DNA to a solid phase support by adding 2 ml of binding buffer containing the support matrix (Promega) and adding it to the syringe column vacuum apparatus. Using the vacuum, filter the matrix.
Using the vacuum, wash with the matrix with 1 ml 80% IPA
Add 2 ml OD desulfonation buffer (0.3 M NaOH in 80% IPA) and incubate at room temperature for 10 minutes. Using the vacuum, remove the buffer.
Using the vacuum, wash with I ml 80% IPA.
3. Remove the column from the syringe and place it in a 1.5 ml microfuge tube Elute 5 x 200 pl followed by addition of 1 ml EB
Table 5 depicts the results obtained.
Table 5 Marker Average Ct SD
Actin 33.1 0.2 APC 31.1 0.2 In this cell line the GSTPI promoter is known to be unmethylated therefore the lack of Ct values for this marker is expected.
Example 4 A modified protocol for fast and efficient bisulfite modification of genomic DNA
The EZ DNA Methylation Kit is provided by Zymo Research (Orange, CA) to perform bisulfite modification of DNA, As per manufacturer's recommendation the DNA sample to be modified is incubated with the bisulfite conversion reagent at 50 C for 12 - 16 hrs. These conditions have been modified to generate comparable quality bisulfite converted DNA in much less time. Several temperatures for different times we~e tested and demonstrated that incubation of DNA sample with bisulfite conversion reagent at 70 C for 1-3 hr provides efficient bisulfite modification comparable to modification conditions recommended in the kit. The data below show methylation specific PCR analysis with DNA samples incubated with bisulfite reagent at different temperatures for different times.
Figure 1 shows that Veridex modified protocol of conversion at 70 C, 2 or 3hr is equivalent to manufacturer recommended 50 C for 16 hrs. This innovation makes this procedure much faster.
Example 5 A quick and efficient protocol for DNA extraction and modification from paraffin Embedded Tissue Extraction of genomic DNA and its bisulfite modification prior to being used in a MSP reaction comprise very significant upstream procedures that are part of this in vitro diagnostic assay. These procedures can be time consuming involving many tedious steps and could also increase chances of sample contamination. By combining the use of a lysis buffer, 10 mM Tris pH 8.0, 150 mM NaCI, 2 mM EDTA, 0.5% SDS including proteinase K and a bisulfite modification kit, a quick and simple sample processing protocol to recover and modify minimal amounts of DNA available from these sample types has been developed.
The following steps were performed:
1. FFPE tissue (Biopsies) (5 x 10 p sections) are placed in Eppendorf tubes.
2. Spin the tube briefly and Add 500 pi Xylene, vortex briefly at medium speed.
3. Incubate at RT for 10 min. (During incubation at least at 2 intervals mix the sample by inverting several times).
4. Centrifuge at full speed for 10 min at room temperature.
5. Remove supernatant by carefully decanting the liquid without losing the pellet.
6. Add 500 pl ethanol (100%, 200 proof) to the pellet to remove residual Xylene. Vortex briefly at medium speed and let the tubes stand for 5 min, mix by inverting several times.
7. Centrifuge at full speed for 10 min at room temperature.
8. Remove the ethanol by carefully decanting the liquid without losing the pellet.
9. Repeat steps 7-10. Make sure to decant most of the liquid in this step.
10. Incubate the open microcentrifuge tube at 50 - 55 C for 10 - 15 min in an oven to evaporate residual ethanol. Before moving to next step make sure all ethanol has evaporated. If not incubate longer.
11. Add 40 pl of TNES lysis buffer (10 mM Tris pH 8.0, 150 mM NaCI, 2 mM EDTA, 0.5% SDS) and suspend the tissue by flicking the tube.
12. Add 10 Nl Proteinase K (20 mg/ml), vortex briefly, spin very briefly.
13. Incubate the sample at 56 C O/N in a heat block with shaking at 500 rpm.
14. Next morning spin the tubes briefly and check the tissue for complete digestion. If there is any left over tissue add 2pI fresh Proteinase K (20 mg/ml), mix by gentle vortexing and incubate another 1 hr at 56 C, 500 rpm in heat block.
7. Centrifuge at full speed for 10 min at room temperature.
8. Remove the ethanol by carefully decanting the liquid without losing the pellet.
9. Repeat steps 7-10. Make sure to decant most of the liquid in this step.
10. Incubate the open microcentrifuge tube at 50 - 55 C for 10 - 15 min in an oven to evaporate residual ethanol. Before moving to next step make sure all ethanol has evaporated. If not incubate longer.
11. Add 40 pl of TNES lysis buffer (10 mM Tris pH 8.0, 150 mM NaCI, 2 mM EDTA, 0.5% SDS) and suspend the tissue by flicking the tube.
12. Add 10 Nl Proteinase K (20 mg/ml), vortex briefly, spin very briefly.
13. Incubate the sample at 56 C O/N in a heat block with shaking at 500 rpm.
14. Next morning spin the tubes briefly and check the tissue for complete digestion. If there is any left over tissue add 2pI fresh Proteinase K (20 mg/ml), mix by gentle vortexing and incubate another 1 hr at 56 C, 500 rpm in heat block.
15. Incubate tubes at 70 C x 10 min on the heat block, spin and store at -20 C for long-term storage or proceed directly for Bisulfite modification of extracted DNA using a commercially available DNA modification kit from ZymoResearch.
16. Add 5 pl of M-Dilution Buffer directly to 45 pl of tissue lysate 17. Mix sample by flicking or pipetting up and down. Spin the sample briefly. Incubate the sample at 37 C for 15 minutes in a heat block with shaking at 1100 rpm.
During the 15 min incubation, prepare CT Conversion Reagent (as per manufacturer's instructions).
During the 15 min incubation, prepare CT Conversion Reagent (as per manufacturer's instructions).
18. After the above 15 minutes incubation, add 100 pi of the prepared CT
Conversion Reagent (after briefly spinning) to each sample and vortex lightly (The sample may turn cloudy). Spin the sample briefly. Incubate the sample at 70 C for 3 hr with the heating block (shaking at 1100 rpm) covered with aluminum foil. (The CT Conversion Reagent is light sensitive, so try to minimize reaction's exposure to light).
Conversion Reagent (after briefly spinning) to each sample and vortex lightly (The sample may turn cloudy). Spin the sample briefly. Incubate the sample at 70 C for 3 hr with the heating block (shaking at 1100 rpm) covered with aluminum foil. (The CT Conversion Reagent is light sensitive, so try to minimize reaction's exposure to light).
19. Spin the sample down briefly. Incubate the sample on ice for 10 min.
20. Add 400 pl of M-Binding buffer to the sample and mix by pipetting up 5 and down 21. Load all the supernatant (including any precipitate) onto a Zymo-Spin I
Column and place column into a 2 ml collection tube and centrifuge at maximum speed for 15 - 30 seconds. Discard the flow-through 22. Add 200 pl of M-Wash Buffer to the column.
10 23. Centrifuge at maximum speed for 15 - 30 second.s. Discard the flow-through.
24. Add 200 NI of M-Desulfonation Buffer to the column and let the column stand at room temperature for 15 minutes.
25. Centrifuge at maxirrium speed for 15 -30 seconds. Discard the*
15 flow-through.
26. Add 200 pl of M-Wash Buffer to the column.
27. Centrifuge at maximum speed for 15 - 30 seconds.
28. Add another 200 pl of M-Wash Buffer to the column.
29. Centrifuge at maximum speed for 30 sec (A longer spinning duration for this last wash is necessary for complete removal of wash buffer residues).
Discard the flow-through.
30. Place the column into a clean 1.5 ml tube.
31. Add 25 pl of M-elution buffer directly to the column matrix. Let the column stand for 1 min at RT. Centrifuge at maximum speed for 1 minute to elute the DNA.
32. Store the eluted DNA at -80 C.
33. Use 5 uI in MSP reaction.
The protocol desctibed above excludes the use of a DNA purification kit prior to bisulfite modification, thereby, reducing sample processing times, preventing DNA losses during purification, reducing cost, and reducing chances of contamination.
Table 6 shows that using the tissue lysate directly for bisulfite modification of DNA gives comparable and even lower Cts than purified DNA
using Qiagen DNA isolation kit. Thus further purification of DNA is not required prior to DNA modification using ZymoResearch EZ DNA methylation kit. Also, the data show that combining TNES/PK digestion and EZ DNA methylation kit yields more DNA sample.
Table 6 FFPE Tissue DNA extraction procedure 3-actin Ct GSTP1 Ct 2 x 5 sections Qiagen DNA isolation kit 30.1 30.9 2 x 5 11 sections TNES/PK digestion 25.4 26.7 Table 7shows that direct lysate from FFPE biopsy tissue can be used successfully for downstream DNA modification with comparable and even better results as compared to using Qiagen DNA isolation kit, thus avoiding unnecessary DNA purification steps and losses.
Table 7 actin Av Cts 3 actin Av Cts Prostate core Biopsies TNES/PK protocol Qia en DNA isolation Sample prep 40 micron (50 micron) J r.~ai ..`.u"e!'' ;~
~~ Z ..-110i eIUtIOf1.~N0 ~ ~ 1' ~2 YsY~,it=~ ~ FRis, 4 .s r .w.~. ,... S ZiS:'. f}r 1 R t{ "u,' ~F a ~. I.n ut,an P.C.,R~n~~ ~ ~ 5 I T~~ ~~i~~
;~
60A 34.45 33.95 6081 32.75 34.30 60B2 32.90 33.25 64A 33.30 34.20 64B 35.70 undetermined DNA methylation assay is developed to be used on patient samples such as archived formalin-fixed, paraffin-embedded tissues, freshly collected urine and blood samples that comprise an invaluable resource for translational studies of cancer and a variety of other diseases. Sample processing is a key upstream part of this diagnostic assay. Conventionally, DNA is purified from these sample types by using standard phenol-chloroform extraction or column based procedures and then subjected to bisulfite modification procedures.
Several commercial kits exist for purification of DNA from paraffin embedded archived tissues, and body fluids. However, loses during such extensive purification procedures can significantly reduce DNA yields when very small amount of starting tissue or body fluid sample type is available. Low DNA
yields can severely impact the downstream assay performance and can also be time consuming. To avoid DNA loses some studies have used digested tissue lysate directly for bisulfite modification of genomic DNA using standard in solution bisulfite modification protocols. The protocol developed in this invention (referred to as TNES protocol) quickly and efficiently extracts and bisulfite modifies genomic DNA by using the deproteinized lysed tissue extract or lysed cells from urine sediment and directly using this with a commercially.
available DNA methylation kit such as ZymoResearch EZ for downstream bisulfite modification without any further purification steps. In addition, the.
present invention improves multiplex PCR assay performance by minimizing loss-during additional purification steps.
Example 6 Processing DNA samples from.urine A. Protocol for DNA extraction from urine Samples (TNES protocol) 1. After collection, urine is to be maintained at 4 C until processed.
2. Urine is placed into a labeled 50 ml Falcon polypropylene tube and LNCap cells (10,000 cells/50 ml) representing shedded tumor cells in a prostate cancer patient are spiked per tube. Then the cells and particulates are pelleted by centrifugation at 3,000 x g at 4 C.
3. Following centrifugation, carefully decant the urine supernatant into sterile labeled 50 ml tube and perform pellet washings in 2 steps.
4. For the first wash, the pellet is washed at 4 C with 40 ml of cold PBS in the original 50 mi tube, gently invert the tube several times to resuspend the pellet, and centrifuge at 3,000 x g. Aspirate the PBS wash.using a vacuum attached to a long narrow glass or plastic tube (drawn-out Pasteur pipette or long plastic tip) to remove as much of the wash as possible and to prevent dislodging of the pellet over a large area of the tube (discard wash).
5. For the second wash, the pellet is resuspended in a smaller volume of 1 ml of cold PBS by gently pipetting up and down with a Pipetman. Once the pellet is suspended, then transfer from the 50 mi tube to a 1.5 ml microcentrifuge tube. With an additional 0.4 ml PBS, rinse the tip and the 50 ml tube to recover as much of pellet as possible and combine with the original 1 ml in the 1.5 ml tube.
6. Centrifuge at 10,000 x g for 5 min and remove the wash by vacuum aspiration with a drawn out pipette/plastic tip. Use slight tilting of the tube to remove as much of the liquid as possible (discard wash). The tube containing the washed urine pellet is then placed into the sarne box as the 50 ml tube of ciarified urine and stored at -20 C until shipping.
7. To -100 pi of washed pellet add 100 pi TNES lysis buffer (10 mM Tris pH
8.0, 150 mM NaCI, 2 mM EDTA, 0.5% SDS), incubated ~@ 56 C for 30 min.
and then stored at -20 C until processing with bisulfite modification kit (see below, part II). In case of cells only, 20 pi TNES buffer was added to 20 NI
cell suspension.
II. Sodium Bisulfite Modification of genomic DNA using EZ-DNA methylation kit from ZymoResearch The EZ DNA Methylation Kit is provided by Zymo Research (Orange, CA) to perform bisulfite modification- of DNA. As per manufacturer's recommendation the DNA sample to be modified is incubated with the bisulfite conversion reagent at 50 C for 12 - 16 hrs. These conditions have now been modified to generate comparable quality bisulfite converted DNA in much less time. Several temperatures and' different times were tested and it was demonstrated that incubation of DNA sample with bisulfite conversion reagent at 70 C for 1 - 3 hr provides efficient bisulfite modification comparable to modification conditions recommended in the kit The protocol is as follows for processing urine samples:
M-Wash Buffer (Prepare before starting using the kit) Preparation of M-Wash buffer: Add 24 ml absolute ethanol to the M-Wash buffer Concentrate to make the final M-Wash buffer for D5001 (Use 96 ml Ethanol for D5002):
1. DNA modification procedure a. Add 5 pi of M-Dilution Buffer directly to 45 pl of urine lysate or for the higher sample volume scale up M-Dilution Buffer and urine crude lysate proportionally. For instance, for 150 pi urine lysate add 20 pi M-dilution buffer and 30 pi water (total of 200 NI).
b. Mix sample by flicking or pipetting up and down. Spin the sample briefly.
Incubate the sample at 37 C for 15 min in a heat block with shaking at 1100 rpm.
During the 15 min incubation, prepare CT Conversion Reagent (as per manufacturer's instructions).
c. After the above 15 minutes incubation, add 100 pl of the prepared CT ' Conversion Reagent (after briefly spinning)-to each sample (or add 400 pl CT reagent for a scaled up protocol) and vortex lightly (the sample may turn cloudy). Spin the sample briefly. Incubate the sample at 70 C for 3 hr with the heating block (shaking at 1100 rpm) covered with aluminum foil. (The CT Conversion Reagent is light sensitive, so try to minimize reaction's exposure to light).
2. Desalting a. Spin the sample down briefly. Incubate the sample on ice for 10 min. In the case of the higher volume of urine sample, aliquot into two tubes of 300 NI each. *
b. Add 400 pl of M-Binding buffer to the sample and mix by pipetting up and down or for scaled up urine samples add 800 pl of M-Binding buffer to each aliquot, mixed and quickly spun.
c. Load all the supernatant (including any precipitate) onto a 2:ymo-Spin I
Column and place column into a 2 ml collection tube and centrifuge at maximum speed for 15 - 30 seconds. Discard the flow-through. For a higher sample volume, this step is repeated by adding supernatant from each aliquoted tube one at a time on the column and centrifuging until all of the sample is loaded onto the column.
d. Add 200 pl of M-Wash Buffer to the column.
e. Centrifuge at maximum speed for 15 - 30 seconds. Discard the flow-through.
3. Desulfonation, 2"d desalting and elution a. Add 200 NI of M-Desulfonation Buffer to the column and let the column stand at room temperature for 15 minutes.
b. Centrifuge at maximum speed for 15 - 30 seconds. Discard the flow-through.
c. Add 200 pl of M-Wash Buffer to the column.
d. Centrifuge at maximum speed for 15 - 30 seconds.
e. Add another 200 pl of M-Wash Buffer to the column.
f. Centrifuge at maximum speed for 30 sec (a longer spinning duration for this last wash is necessary for complete remoVal of wash buffer residues).
Discard the flow-through.
g. Place the column into a clean 1.5 ml tube.
5 h. Add 25 pl of M-elution buffer directly to the column matrix. Let the column stand for 1 min at RT. Centrifuge at maximum speed for 1 minute to elute the DNA..
I. Store the eluted DNA at -80 C.
j. Use 5 NI in MSP reaction.
10 Results:
The protocol described above excludes the use of a DNA purification kit prior to bisulfite modification, thereby, reducing sample processing times, preventing DNA losses during purification, reducing cost,'and reducing chances =
of contamination).
15 Table 8 shows end results from MSP assay on Cepheid Smart Cycler with DNA samples processed by TNES protocol from 50 ml of urine. Better f3-actin and GSTP1 Cts (up to 3 Cts lower) are observed using above described TNES/PK digestion protocol over use of purified DNA using commercially available Qiagen DNA isolation kit (QiAmp Viral RNA kit). Thus further 20 purification of DNA is not required prior to DNA modification using this method.
Also, the data show that combining TNES/PK digestion and EZ DNA
methylation kit yields more DNA sample.
Table 8. TNES protocol vs. Qiagen DNA isolation kit (10,000 LNCaP cells/50 ml urine) INPUT v ac#~n Ct"vsGSTP1 Ct extraction rotocol 50 ml Urine / 10 LNCaP cells NES 9.9 32.9 50 mi Urine / 10 LNCaP cells Qiagen 30.9 34.6.
~ ,~v rY ' u :ar. w 1;0 sLNCaP~,~scells ~ ~ NES~ W~ 21~5~~
'=~''`~'~k a "~'"~~*'' S `~39~~ i. '~~ , "'4 I LNCaP~cells ~
lfx. r=J:,~+~~ '.;~~~~F.~'.`x~i~.~.'~t:.',r~õ~ .f4i. .t~'~'4ii~
~`i`.~.c~l.,~"f~.'~~ - ~~y.,~ :'i?. L`s.l.`
Results with TNES extraction protocol are even more compelling on serial dilutions of LNCaP prostate cells (range of 10,000 to 100 spiked per 50 ml pooled urine from healthy donors). Combined protocol for DNA extraction followed directly by bisulfite modification allows to improve sensitivity of the prostate methylation assay by 10 fold (Table 9) as compared with two commercial kits combined. TNES protocol allows detection of 100 cells per 50 ml urine, the level which is undetectable by Qiagen protocol using both Ct value and copy number analysis.
Table 9. TNES protocol vs. Qiagen DNA isolation kit (LNCaP cells: 10,000, 1000 and 100/50 ml'urine).
TNES-ZR BMK protocol Qia en-ZR BMK protocol Task GSTP GSTP Ratio Gst-Pi GST GSTP1 Ratio Gst-Pi # cells/mi Ct Copies M/Q-actin P1 Ct Copies M/G3-actin urine co ies X 1000 co ies X 1000 /50 29.70 6365 487 30.88 3051 575 10 /50 31.10 2651 113 33.63 546 68 10 /50 31.38 2232 126 33.83 482 58 10/50 35.05 224 17 38.93 20 2 10 /50 .34.43 331 22 38.58 25 3 10I50 38.60 24 2 00.00 0 0 10 /50 0.00 0 0 00.00 0 0 Ct values, Copy numbers and methylation ratios are presented for sample replicates of the same cell load in 50 mi urine Although the foregoing invention has been described in some detail by 10 way of illustration and example for purposes of clarity of understanding, the descriptions and examples should not be construed as limiting the scope of the invention.
REFERENCES
20020197639, 2003002221.5, 20030032026, 20030082600, 20030087258, =
20030096289,20030129620,20030148290,20030157510,20030170684, 20030215842,20030224040,20030232351,20040023279,20040038245, 20040048275, 20040072197, 20040086944, 20040101843, 20040115663, 20040132048, 20040137474, 20040146866, 2004014fi868, 20040152080, 20040171118, 20040203048, 20040241704, 20040248090, 20040248120,-20040265814,20050009059,20050019762,20050026183,20050053937, 20050064428,20050069879,20050079527,20050089870,20050130172, 20050153296,20050196792,20050208491,20050208538,20050214812, 20050233340,20050239101,20050260630,20050266458,20050287553, 20070148670 and US patent numbers 5786146, 6214556, 6251594, 6331393 and'6335165 Chuang et al. (2007) E i enetics and microRNAs Ped Res 61:24R-29R
Emmerechts et al. (2007) Post-transcriptional modification mapping in the Colstridium acetobutylicum 16S rRNA by mass spectrometry and reverse transcriptase assays Nucl Acids Res 35:3494-3503 Frommer et al. (1992) A genornic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands Proc Natt Acad Sci USA 89:1827-31 Grunau et al. (2001) Bisulfite genomic sequencing: systematic investigation of critical ex erimental parameters Nucl Acids Res 29:E65-5.
Hurd et al. (2007) Detection of ROS-sensitive thiol proteins by redox-difference gel electrophoresis (Redox-DIGE) J Biol Chem (in press) epub Jin et al. (2007) Influence or stereochemistry and redox potentials on the singles- and double-strand DNA cleavage efficiency of Cu(II) and Ni(iI) L s-GI -His-derived ATCUN metallo e tides JACS 129:8353-8361 Oakeley (1999) DNA methylation analysis: a review of current methodologies Pharmacol Thera 84:389-400 Rathi et al. (2003) Aberrant methylation of the HIC1 promoter is a frequent event in specific pediatric neoplasms Clin Cancer Res 9:3674-33678 Rein et al. (1998) Identifying 5-methylcytosine and related modifications in DNA
genomes Nucl Acids Res 26:2255-2264 Sambrook et al. (2000) Molecular Cloning: A Laboratory Manual (3r Ed) Cold Spring Harbor Laboratories Wu et al. (2007) Computer modeling of mitochondrial TCA cycle, oxidative phosphorylation, metabolite transport, and electrophysiology J Biol Chem (in press) epub
Column and place column into a 2 ml collection tube and centrifuge at maximum speed for 15 - 30 seconds. Discard the flow-through 22. Add 200 pl of M-Wash Buffer to the column.
10 23. Centrifuge at maximum speed for 15 - 30 second.s. Discard the flow-through.
24. Add 200 NI of M-Desulfonation Buffer to the column and let the column stand at room temperature for 15 minutes.
25. Centrifuge at maxirrium speed for 15 -30 seconds. Discard the*
15 flow-through.
26. Add 200 pl of M-Wash Buffer to the column.
27. Centrifuge at maximum speed for 15 - 30 seconds.
28. Add another 200 pl of M-Wash Buffer to the column.
29. Centrifuge at maximum speed for 30 sec (A longer spinning duration for this last wash is necessary for complete removal of wash buffer residues).
Discard the flow-through.
30. Place the column into a clean 1.5 ml tube.
31. Add 25 pl of M-elution buffer directly to the column matrix. Let the column stand for 1 min at RT. Centrifuge at maximum speed for 1 minute to elute the DNA.
32. Store the eluted DNA at -80 C.
33. Use 5 uI in MSP reaction.
The protocol desctibed above excludes the use of a DNA purification kit prior to bisulfite modification, thereby, reducing sample processing times, preventing DNA losses during purification, reducing cost, and reducing chances of contamination.
Table 6 shows that using the tissue lysate directly for bisulfite modification of DNA gives comparable and even lower Cts than purified DNA
using Qiagen DNA isolation kit. Thus further purification of DNA is not required prior to DNA modification using ZymoResearch EZ DNA methylation kit. Also, the data show that combining TNES/PK digestion and EZ DNA methylation kit yields more DNA sample.
Table 6 FFPE Tissue DNA extraction procedure 3-actin Ct GSTP1 Ct 2 x 5 sections Qiagen DNA isolation kit 30.1 30.9 2 x 5 11 sections TNES/PK digestion 25.4 26.7 Table 7shows that direct lysate from FFPE biopsy tissue can be used successfully for downstream DNA modification with comparable and even better results as compared to using Qiagen DNA isolation kit, thus avoiding unnecessary DNA purification steps and losses.
Table 7 actin Av Cts 3 actin Av Cts Prostate core Biopsies TNES/PK protocol Qia en DNA isolation Sample prep 40 micron (50 micron) J r.~ai ..`.u"e!'' ;~
~~ Z ..-110i eIUtIOf1.~N0 ~ ~ 1' ~2 YsY~,it=~ ~ FRis, 4 .s r .w.~. ,... S ZiS:'. f}r 1 R t{ "u,' ~F a ~. I.n ut,an P.C.,R~n~~ ~ ~ 5 I T~~ ~~i~~
;~
60A 34.45 33.95 6081 32.75 34.30 60B2 32.90 33.25 64A 33.30 34.20 64B 35.70 undetermined DNA methylation assay is developed to be used on patient samples such as archived formalin-fixed, paraffin-embedded tissues, freshly collected urine and blood samples that comprise an invaluable resource for translational studies of cancer and a variety of other diseases. Sample processing is a key upstream part of this diagnostic assay. Conventionally, DNA is purified from these sample types by using standard phenol-chloroform extraction or column based procedures and then subjected to bisulfite modification procedures.
Several commercial kits exist for purification of DNA from paraffin embedded archived tissues, and body fluids. However, loses during such extensive purification procedures can significantly reduce DNA yields when very small amount of starting tissue or body fluid sample type is available. Low DNA
yields can severely impact the downstream assay performance and can also be time consuming. To avoid DNA loses some studies have used digested tissue lysate directly for bisulfite modification of genomic DNA using standard in solution bisulfite modification protocols. The protocol developed in this invention (referred to as TNES protocol) quickly and efficiently extracts and bisulfite modifies genomic DNA by using the deproteinized lysed tissue extract or lysed cells from urine sediment and directly using this with a commercially.
available DNA methylation kit such as ZymoResearch EZ for downstream bisulfite modification without any further purification steps. In addition, the.
present invention improves multiplex PCR assay performance by minimizing loss-during additional purification steps.
Example 6 Processing DNA samples from.urine A. Protocol for DNA extraction from urine Samples (TNES protocol) 1. After collection, urine is to be maintained at 4 C until processed.
2. Urine is placed into a labeled 50 ml Falcon polypropylene tube and LNCap cells (10,000 cells/50 ml) representing shedded tumor cells in a prostate cancer patient are spiked per tube. Then the cells and particulates are pelleted by centrifugation at 3,000 x g at 4 C.
3. Following centrifugation, carefully decant the urine supernatant into sterile labeled 50 ml tube and perform pellet washings in 2 steps.
4. For the first wash, the pellet is washed at 4 C with 40 ml of cold PBS in the original 50 mi tube, gently invert the tube several times to resuspend the pellet, and centrifuge at 3,000 x g. Aspirate the PBS wash.using a vacuum attached to a long narrow glass or plastic tube (drawn-out Pasteur pipette or long plastic tip) to remove as much of the wash as possible and to prevent dislodging of the pellet over a large area of the tube (discard wash).
5. For the second wash, the pellet is resuspended in a smaller volume of 1 ml of cold PBS by gently pipetting up and down with a Pipetman. Once the pellet is suspended, then transfer from the 50 mi tube to a 1.5 ml microcentrifuge tube. With an additional 0.4 ml PBS, rinse the tip and the 50 ml tube to recover as much of pellet as possible and combine with the original 1 ml in the 1.5 ml tube.
6. Centrifuge at 10,000 x g for 5 min and remove the wash by vacuum aspiration with a drawn out pipette/plastic tip. Use slight tilting of the tube to remove as much of the liquid as possible (discard wash). The tube containing the washed urine pellet is then placed into the sarne box as the 50 ml tube of ciarified urine and stored at -20 C until shipping.
7. To -100 pi of washed pellet add 100 pi TNES lysis buffer (10 mM Tris pH
8.0, 150 mM NaCI, 2 mM EDTA, 0.5% SDS), incubated ~@ 56 C for 30 min.
and then stored at -20 C until processing with bisulfite modification kit (see below, part II). In case of cells only, 20 pi TNES buffer was added to 20 NI
cell suspension.
II. Sodium Bisulfite Modification of genomic DNA using EZ-DNA methylation kit from ZymoResearch The EZ DNA Methylation Kit is provided by Zymo Research (Orange, CA) to perform bisulfite modification- of DNA. As per manufacturer's recommendation the DNA sample to be modified is incubated with the bisulfite conversion reagent at 50 C for 12 - 16 hrs. These conditions have now been modified to generate comparable quality bisulfite converted DNA in much less time. Several temperatures and' different times were tested and it was demonstrated that incubation of DNA sample with bisulfite conversion reagent at 70 C for 1 - 3 hr provides efficient bisulfite modification comparable to modification conditions recommended in the kit The protocol is as follows for processing urine samples:
M-Wash Buffer (Prepare before starting using the kit) Preparation of M-Wash buffer: Add 24 ml absolute ethanol to the M-Wash buffer Concentrate to make the final M-Wash buffer for D5001 (Use 96 ml Ethanol for D5002):
1. DNA modification procedure a. Add 5 pi of M-Dilution Buffer directly to 45 pl of urine lysate or for the higher sample volume scale up M-Dilution Buffer and urine crude lysate proportionally. For instance, for 150 pi urine lysate add 20 pi M-dilution buffer and 30 pi water (total of 200 NI).
b. Mix sample by flicking or pipetting up and down. Spin the sample briefly.
Incubate the sample at 37 C for 15 min in a heat block with shaking at 1100 rpm.
During the 15 min incubation, prepare CT Conversion Reagent (as per manufacturer's instructions).
c. After the above 15 minutes incubation, add 100 pl of the prepared CT ' Conversion Reagent (after briefly spinning)-to each sample (or add 400 pl CT reagent for a scaled up protocol) and vortex lightly (the sample may turn cloudy). Spin the sample briefly. Incubate the sample at 70 C for 3 hr with the heating block (shaking at 1100 rpm) covered with aluminum foil. (The CT Conversion Reagent is light sensitive, so try to minimize reaction's exposure to light).
2. Desalting a. Spin the sample down briefly. Incubate the sample on ice for 10 min. In the case of the higher volume of urine sample, aliquot into two tubes of 300 NI each. *
b. Add 400 pl of M-Binding buffer to the sample and mix by pipetting up and down or for scaled up urine samples add 800 pl of M-Binding buffer to each aliquot, mixed and quickly spun.
c. Load all the supernatant (including any precipitate) onto a 2:ymo-Spin I
Column and place column into a 2 ml collection tube and centrifuge at maximum speed for 15 - 30 seconds. Discard the flow-through. For a higher sample volume, this step is repeated by adding supernatant from each aliquoted tube one at a time on the column and centrifuging until all of the sample is loaded onto the column.
d. Add 200 pl of M-Wash Buffer to the column.
e. Centrifuge at maximum speed for 15 - 30 seconds. Discard the flow-through.
3. Desulfonation, 2"d desalting and elution a. Add 200 NI of M-Desulfonation Buffer to the column and let the column stand at room temperature for 15 minutes.
b. Centrifuge at maximum speed for 15 - 30 seconds. Discard the flow-through.
c. Add 200 pl of M-Wash Buffer to the column.
d. Centrifuge at maximum speed for 15 - 30 seconds.
e. Add another 200 pl of M-Wash Buffer to the column.
f. Centrifuge at maximum speed for 30 sec (a longer spinning duration for this last wash is necessary for complete remoVal of wash buffer residues).
Discard the flow-through.
g. Place the column into a clean 1.5 ml tube.
5 h. Add 25 pl of M-elution buffer directly to the column matrix. Let the column stand for 1 min at RT. Centrifuge at maximum speed for 1 minute to elute the DNA..
I. Store the eluted DNA at -80 C.
j. Use 5 NI in MSP reaction.
10 Results:
The protocol described above excludes the use of a DNA purification kit prior to bisulfite modification, thereby, reducing sample processing times, preventing DNA losses during purification, reducing cost,'and reducing chances =
of contamination).
15 Table 8 shows end results from MSP assay on Cepheid Smart Cycler with DNA samples processed by TNES protocol from 50 ml of urine. Better f3-actin and GSTP1 Cts (up to 3 Cts lower) are observed using above described TNES/PK digestion protocol over use of purified DNA using commercially available Qiagen DNA isolation kit (QiAmp Viral RNA kit). Thus further 20 purification of DNA is not required prior to DNA modification using this method.
Also, the data show that combining TNES/PK digestion and EZ DNA
methylation kit yields more DNA sample.
Table 8. TNES protocol vs. Qiagen DNA isolation kit (10,000 LNCaP cells/50 ml urine) INPUT v ac#~n Ct"vsGSTP1 Ct extraction rotocol 50 ml Urine / 10 LNCaP cells NES 9.9 32.9 50 mi Urine / 10 LNCaP cells Qiagen 30.9 34.6.
~ ,~v rY ' u :ar. w 1;0 sLNCaP~,~scells ~ ~ NES~ W~ 21~5~~
'=~''`~'~k a "~'"~~*'' S `~39~~ i. '~~ , "'4 I LNCaP~cells ~
lfx. r=J:,~+~~ '.;~~~~F.~'.`x~i~.~.'~t:.',r~õ~ .f4i. .t~'~'4ii~
~`i`.~.c~l.,~"f~.'~~ - ~~y.,~ :'i?. L`s.l.`
Results with TNES extraction protocol are even more compelling on serial dilutions of LNCaP prostate cells (range of 10,000 to 100 spiked per 50 ml pooled urine from healthy donors). Combined protocol for DNA extraction followed directly by bisulfite modification allows to improve sensitivity of the prostate methylation assay by 10 fold (Table 9) as compared with two commercial kits combined. TNES protocol allows detection of 100 cells per 50 ml urine, the level which is undetectable by Qiagen protocol using both Ct value and copy number analysis.
Table 9. TNES protocol vs. Qiagen DNA isolation kit (LNCaP cells: 10,000, 1000 and 100/50 ml'urine).
TNES-ZR BMK protocol Qia en-ZR BMK protocol Task GSTP GSTP Ratio Gst-Pi GST GSTP1 Ratio Gst-Pi # cells/mi Ct Copies M/Q-actin P1 Ct Copies M/G3-actin urine co ies X 1000 co ies X 1000 /50 29.70 6365 487 30.88 3051 575 10 /50 31.10 2651 113 33.63 546 68 10 /50 31.38 2232 126 33.83 482 58 10/50 35.05 224 17 38.93 20 2 10 /50 .34.43 331 22 38.58 25 3 10I50 38.60 24 2 00.00 0 0 10 /50 0.00 0 0 00.00 0 0 Ct values, Copy numbers and methylation ratios are presented for sample replicates of the same cell load in 50 mi urine Although the foregoing invention has been described in some detail by 10 way of illustration and example for purposes of clarity of understanding, the descriptions and examples should not be construed as limiting the scope of the invention.
REFERENCES
20020197639, 2003002221.5, 20030032026, 20030082600, 20030087258, =
20030096289,20030129620,20030148290,20030157510,20030170684, 20030215842,20030224040,20030232351,20040023279,20040038245, 20040048275, 20040072197, 20040086944, 20040101843, 20040115663, 20040132048, 20040137474, 20040146866, 2004014fi868, 20040152080, 20040171118, 20040203048, 20040241704, 20040248090, 20040248120,-20040265814,20050009059,20050019762,20050026183,20050053937, 20050064428,20050069879,20050079527,20050089870,20050130172, 20050153296,20050196792,20050208491,20050208538,20050214812, 20050233340,20050239101,20050260630,20050266458,20050287553, 20070148670 and US patent numbers 5786146, 6214556, 6251594, 6331393 and'6335165 Chuang et al. (2007) E i enetics and microRNAs Ped Res 61:24R-29R
Emmerechts et al. (2007) Post-transcriptional modification mapping in the Colstridium acetobutylicum 16S rRNA by mass spectrometry and reverse transcriptase assays Nucl Acids Res 35:3494-3503 Frommer et al. (1992) A genornic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands Proc Natt Acad Sci USA 89:1827-31 Grunau et al. (2001) Bisulfite genomic sequencing: systematic investigation of critical ex erimental parameters Nucl Acids Res 29:E65-5.
Hurd et al. (2007) Detection of ROS-sensitive thiol proteins by redox-difference gel electrophoresis (Redox-DIGE) J Biol Chem (in press) epub Jin et al. (2007) Influence or stereochemistry and redox potentials on the singles- and double-strand DNA cleavage efficiency of Cu(II) and Ni(iI) L s-GI -His-derived ATCUN metallo e tides JACS 129:8353-8361 Oakeley (1999) DNA methylation analysis: a review of current methodologies Pharmacol Thera 84:389-400 Rathi et al. (2003) Aberrant methylation of the HIC1 promoter is a frequent event in specific pediatric neoplasms Clin Cancer Res 9:3674-33678 Rein et al. (1998) Identifying 5-methylcytosine and related modifications in DNA
genomes Nucl Acids Res 26:2255-2264 Sambrook et al. (2000) Molecular Cloning: A Laboratory Manual (3r Ed) Cold Spring Harbor Laboratories Wu et al. (2007) Computer modeling of mitochondrial TCA cycle, oxidative phosphorylation, metabolite transport, and electrophysiology J Biol Chem (in press) epub
Claims (38)
1. A method of modifying a macromolecule without prior extraction from a sample comprising the steps of a. converting the macromolecule in the sample with a chemical b. removing or converting chemical intermediates, if necessary; and c. purifying the resulting modified macromolecule.
2. The method according to claim 1 wherein the macromolecules are selected from the group consisting of DNA, RNA, cellular metabolites, lipids, carbohydrates and proteins.
3. The method according to claim 1 wherein the macromolecule is DNA and is selected from viral, nucleic, mitochondrial, plastid, bacterial and synthetic.
4. The method according to claim 1 wherein the macromolecule is RNA and is selected from rtRNA, tRNA, miRNA, rRNA and mRNA.
5. The method according to claim 1 wherein the macromolecule is a cellular metabolite and is selected from those produced by a metabolic cycle or enzymatic effects.
6. The method according to claim 1 wherein the macromolecule is lipid and is selected from liposomes, cell membrane lipids, intracellular membrane lipids and extracellular lipids.
7. The method according to claim 1 wherein the macromolecule is carbohydrate and is selected from protein-bound carbohydrates and nucleic acid-bound carbohydrates.
8. The method according to claim 1 wherein the macromolecule is protein and is selected from intracellular and extracellular.
9. The method according to claim 3 wherein the modification is selected from bisulfite and biotinylation.
10. The method according to claim 4 wherein the modification is selected from fluorination and methylation.
11. The method according to claim 6 wherein the modification is selected from heating, liposome formation, micelle formation, uni-layer formation and bilayer formation.
12. The method according to claim 7 wherein the modification is selected from oxidation, de-oxidation, amination and de-amination.
13. The method according to claim 8 wherein the modification is selected from phosphorylation, dephosphorylation, methylation, biotinylation, amination, deamination, glycosylation and deglycosylation.
14. The method according to claim 1 wherein the sample is selected from tissue, body fluid, a biopsy sample, and preserved tissue.
15. The method according to claim 1 wherein the sample is tissue and is selected from whole organs, dissected organs, epithelium, neural, gastrointestinal, muscle, cardiac, mucosal and endothelium.
16. The method according to claim 1 wherein the sample is body fluid and is selected from whole blood, plasma, urine, saliva, vitreous and serum.
17. The method according to claim 1 wherein the sample is a biopsy sample and is selected from fine needle aspirate, tissue section and skin sample.
18. The method according to claim 1 wherein the sample is preserved tissue and is selected from fresh frozen, paraffin embedded and preserved in a preservation reagent.
19. The method according to claim 18 wherein the preservation reagent is selected from formalin, RNAlater.TM.and dimethylsulfoxide.
20. The method according to claim 1 wherein the purification is selected from particle-based, precipitation, centrifugation, electrophoretic and charge switch.
21. The method according to claim 20 wherein the purification is particle-based and is selected from affinity, sizing and magnetic.
22. The method according to claim 21 wherein the sizing particle is selected from silica-based and diatomaceous earth.
23. The method according to claim 20 wherein the electrophoretic separation is by size and/or charge.
24. The method according to claim 20 wherein the electrophoretic separation is by a gel formed of low molecular weight polymers and/or capillary.
25. A method of extracting and modifying DNA comprising the steps of a. obtaining a sample containing DNA;
b. incubating the sample with an amount of a bisulfite and for a time and under conditions sufficient to convert a sufficient amount of the non-methylated cytosine residues in the DNA to uracil resides;
c. applying the DNA in the sample to a column;
d. washing the bound DNA to remove contaminants;
e. incubating the column-bound DNA with a desulfonation reagent for a time and under conditions sufficient for desulfonation to occur;
f. washing the bound DNA to remove the desulfonation-reagent; and g. eluting the bisulfite modified DNA from the column.
b. incubating the sample with an amount of a bisulfite and for a time and under conditions sufficient to convert a sufficient amount of the non-methylated cytosine residues in the DNA to uracil resides;
c. applying the DNA in the sample to a column;
d. washing the bound DNA to remove contaminants;
e. incubating the column-bound DNA with a desulfonation reagent for a time and under conditions sufficient for desulfonation to occur;
f. washing the bound DNA to remove the desulfonation-reagent; and g. eluting the bisulfite modified DNA from the column.
26. The method according to claim 25, wherein the DNA is obtained by a method comprising the steps of:
a. obtaining a cell sample; and b. lysing the cell sample to obtain a lysate.
a. obtaining a cell sample; and b. lysing the cell sample to obtain a lysate.
27. The method according to claim 26 wherein the lysate is from about 0.01 to µg.
28. The method according to claim 27 wherein the lysate is applied directly to the column in step b of claim 25.
29. The method according to claim 25 wherein the lysate is obtained by incubation with a proteinase and/or high salt concentration and/or detergent, sonication, freeze-thaw treatment or mechanical disruption.
30. The method according to claim 25 wherein the bisulfite is sodium bisulfite or meta bisulfite.
31. The method according to claim 25 wherein the incubation conditions of step b are about 1-16 hours at 50-95°C with or without thermocycling.
32. The method according to claim 25 wherein the desulfonation is performed changing the pH.
33. The method according to claim 32 wherein the desulfonation is performed under basic conditions.
34. The method according to claim 33 wherein the conditions include sodium hydroxide and an alcohol.
35. The method according to claim 34 wherein the alcohol is isopropanol or ethanol.
36. The method according to claim 35 wherein the desulfonation occurs from about 0-30 minutes at about 0°C to about 50°C.
37. The method according to claim 36 wherein the desulfonation occurs at about 15 minutes.
38. The method according to claim 36 wherein the desulfonation occurs at room temperature.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81787606P | 2006-06-29 | 2006-06-29 | |
| US60/817,876 | 2006-06-29 | ||
| US82879006P | 2006-10-10 | 2006-10-10 | |
| US60/828,790 | 2006-10-10 | ||
| PCT/US2007/015329 WO2008002680A2 (en) | 2006-06-29 | 2007-06-29 | A method of modifying a macromolecule without prior extraction from a sample |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2656327A1 true CA2656327A1 (en) | 2008-01-03 |
Family
ID=38846340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002656327A Abandoned CA2656327A1 (en) | 2006-06-29 | 2007-06-29 | A method of modifying a macromolecule without prior extraction from a sample |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2041316A4 (en) |
| JP (1) | JP2009542216A (en) |
| KR (1) | KR20090036121A (en) |
| BR (1) | BRPI0713927A2 (en) |
| CA (1) | CA2656327A1 (en) |
| IL (1) | IL196198A0 (en) |
| MX (1) | MX2009000122A (en) |
| WO (1) | WO2008002680A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8298852B2 (en) | 2008-12-29 | 2012-10-30 | Jusung Engineering Co., Ltd. | Thin film type solar cell and method for manufacturing the same |
| EP2407540A1 (en) * | 2010-07-15 | 2012-01-18 | Qiagen GmbH | Method for purifying a target nucleic acid |
| US20150368636A1 (en) * | 2013-01-30 | 2015-12-24 | Exact Sciences Corporation | Treatment of a sample vessel |
| CN107821989B (en) * | 2017-12-04 | 2020-11-17 | 南京农业大学 | Glycosylation method for improving quality of PSE-like chicken breast myofibrillar protein gel |
| US20240417776A1 (en) * | 2020-09-24 | 2024-12-19 | Case Western Reserve University | Compositions and methods for preserving dna methylation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10304219B3 (en) * | 2003-01-30 | 2004-08-19 | Epigenomics Ag | Method for the detection of cytosine methylation patterns with high sensitivity |
-
2007
- 2007-06-29 BR BRPI0713927-6A patent/BRPI0713927A2/en not_active Application Discontinuation
- 2007-06-29 WO PCT/US2007/015329 patent/WO2008002680A2/en active Application Filing
- 2007-06-29 JP JP2009518328A patent/JP2009542216A/en active Pending
- 2007-06-29 EP EP07810136A patent/EP2041316A4/en not_active Withdrawn
- 2007-06-29 CA CA002656327A patent/CA2656327A1/en not_active Abandoned
- 2007-06-29 KR KR1020097001936A patent/KR20090036121A/en not_active Withdrawn
- 2007-06-29 MX MX2009000122A patent/MX2009000122A/en unknown
-
2008
- 2008-12-25 IL IL196198A patent/IL196198A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009542216A (en) | 2009-12-03 |
| EP2041316A2 (en) | 2009-04-01 |
| IL196198A0 (en) | 2009-09-22 |
| EP2041316A4 (en) | 2009-12-09 |
| MX2009000122A (en) | 2009-01-26 |
| BRPI0713927A2 (en) | 2013-01-08 |
| WO2008002680A3 (en) | 2008-11-27 |
| WO2008002680A2 (en) | 2008-01-03 |
| KR20090036121A (en) | 2009-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6096660B2 (en) | Method for isolating target nucleic acids, including small target nucleic acids, in high yield | |
| US10738069B2 (en) | Method for isolating nucleic acids | |
| JP6689251B2 (en) | Method for isolating RNA in high yield | |
| CN110106229B (en) | Method for isolating microvesicles | |
| JP2012502632A (en) | Small RNA isolation method | |
| US20210380966A1 (en) | Method for isolating poly(a) nucleic acids | |
| US20090042290A1 (en) | Method of modifying a macromolecule without prior extraction from a sample | |
| US20080213870A1 (en) | Methods for obtaining modified DNA from a biological specimen | |
| CA2656327A1 (en) | A method of modifying a macromolecule without prior extraction from a sample | |
| CN106232812A (en) | The recovery method of short-chain nucleic acids | |
| US11427815B2 (en) | Nucleic acid purification system using a single wash and elution buffer solution | |
| ES2665280T3 (en) | Methods for the extraction and purification of components of biological samples | |
| US9416357B2 (en) | Method for isolating total RNA from cells | |
| CN119876125B (en) | Reagent for extracting small RNA, method and application thereof | |
| CN106867994B (en) | Rapid precipitation buffer solution applied to plasmid DNA extraction and application thereof | |
| WO2025003501A1 (en) | Nucleic acid preparation | |
| JP2016158558A (en) | DNA and RNA isolation methods | |
| CN120310789A (en) | Eluent for improving nucleic acid recovery efficiency and preparation method and application thereof | |
| AU2017268667A1 (en) | Processes for isolating, amplifying and characterizing DNA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |